On January 16, 2025, Shenzhen Cell Valley successfully held its 2024 Annual Management Summary Meeting. Chaired by Chairman and General Manager Professor Shi Yuanyuan, the meeting was attended by key company executives, including Chief Scientist Professor Wang Jianxun; Feng Yaru (Director of Production and R&D); Zhang Xuefeng (Director of Quality Management); Wei Zheng (Director of the General Manager's Office); Zhao Lijun (Head of R&D); Sun Rui (Head of Marketing); Shi Yunzhu (Head of General Logistics); Wang Lu (Director of the General Affairs Office); Fu Yuchen (Executive Assistant to the Chairman); Zhu Wenxiang (Senior R&D Scientist); Li Rongyou (Deputy Head of Quality Management); and Li Huaxiu (Deputy Head of Production). The meeting aimed to comprehensively review the achievements of the past year, identify existing problems and shortcomings, and outline the development blueprint for 2025.

During the work report session, heads of various departments took the stage one by one. Using detailed data and case studies, they comprehensively showcased their departments' highlights, achievements, and the challenges and opportunities faced over the past year. They also presented their work plans and objectives for the upcoming year.

Subsequently, Chairman Professor Shi Yuanyuan provided comments on the work of all departments in 2024 and delivered a comprehensive and in-depth summary of the group's overall development. He highly commended the remarkable achievements made by various departments over the past year, particularly the major breakthroughs in scientific research innovation and core business revenue. Chairman Shi pointed out that as a leading one-stop solution provider for cell and gene therapy (CGT) in China, Shenzhen Cell Valley has always adhered to its original aspiration of "saving lives and healing patients," dedicating itself to promoting the innovation and application of cell therapy technologies. Over the past year, the company made significant progress in the R&D of novel gene editing delivery systems and established close strategic partnerships with multiple authoritative medical institutions in China, jointly driving the vigorous development of the CGT industry. At the same time, Chairman Shi also highlighted the challenges and deficiencies faced during the company's development, emphasizing that against the backdrop of rapid development in the biopharmaceutical industry and increasingly fierce market competition, Shenzhen Cell Valley needs to continuously strengthen its capabilities and enhance its core competitiveness.

Looking ahead, Chairman Shi expressed full confidence, stating that Shenzhen Cell Valley will continue to uphold its original aspiration and deepen its expertise in the CGT field. In 2025, the company will increase investment in scientific research, optimize its talent structure, strengthen team building, and actively seek cooperation and exchange with other enterprises and institutions. Meanwhile, Shenzhen Cell Valley will actively expand into overseas markets to enhance its brand influence and gradually achieve sustainable development. Chairman Shi emphasized that the company will continue to deepen technical R&D and refine process innovations, using breakthroughs in key areas to facilitate the leapfrog development of the industry and make greater contributions to the cause of human health.

In 2024, the people of Cell Valley upheld their original aspiration, forged ahead with resilience, and constantly broke through self-imposed limits. Looking forward to 2025, all employees of Shenzhen Cell Valley will move forward hand in hand with confidence, deepen technological innovation, and improve service quality. They are committed to contributing to the rapid development of Shenzhen Cell Valley and making positive contributions to the high-quality development of the cell and gene therapy industry!